Background: Angiogenic and lymphangiogenic factors (ALFs) may play an important role in inflammatory bowel disease (IBD). Our aims were to evaluate levels of ALFs in serum and the colonic mucosa culture supernatant (MCS) of patients with active and quiescent IBD and healthy subjects and to correlate them with the endoscopic, clinical and histological activity and with acute-phase reactants. Methods: This is a prospective study of 28 controls and 72 IBD patients. Serum and MCS concentration of VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, PlGF, Ang1, Ang2 and Tie2 were measured by ELISA. Activity was established by specific indexes (CDAI, Mayo score, SES-CD, D'Haens scale and Riley index). Acute-phase reactants were routinely measured. Results: MCS levels of all ALFs except VEGFR3 were higher in patients with endoscopic (p b 0.05), clinical (p b 0.05) and histological (p b 0.01) activity than in those without it. In serum, VEGFA, VEGFC and Ang1 and VEGFA and Ang1 levels were lower in patients in remission than in patients with clinical and histological activity, respectively (p b 0.05). There was a correlation between serum and MCS concentrations for VEGFD, VEGFR3, PlGF and Tie2 (r = 0.25, r = 0.48, r = -0.45 and A v a i l a b l e o n l i n e a t w w w . s c i e n c e d i r e c t . c o m
Introduction
Angiogenesis is defined as the formation of new blood vessels from pre-existing ones. 1 This process occurs during various physiological processes, e.g., embryogenesis, female reproductive cycle, hair growth cycle, wound healing or tissue growth. 2, 3 In physiological angiogenesis, after stabilization and structuralisation of the new formed capillary network, the balance between pro-and antiangiogenic factors returns to baseline levels and the process ends. 4 However, an imbalance between positive and negative regulators probably leads to pathological angiogenesis which has been suggested to promote diseases such as cancer, ischemic cardiovascular disease, diabetic retinopathy and rheumatoid arthritis. 5, 6 In contrast to blood vessels, lymphatic vessel biology is much less understood. Lymphatic vessels carry out important physiological functions including draining excess body fluid from tissues, intestinal fat absorption and immune cell trafficking through the lymph nodes. 3, 7 Several studies have documented the association of lymphangiogenesis with tumour growth and metastatic spread. [8] [9] [10] Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC). The etiology of CD or UC has not been fully elucidated. There is growing clinical and experimental evidence suggesting that the initiation and progression of these inflammatory disorders involve complex interactions among genetic, immune and environmental factors. [11] [12] [13] Recent findings indicate that angiogenesis and lymphangiogenesis also play a crucial role in IBD. [14] [15] [16] [17] [18] [19] New biochemical, molecular and immunohistochemical studies indicate that several families of growth factors, such as the vascular endothelial growth factor (VEGF) family and their receptors, and the angiopoietin system may play an important role in the onset of IBD. To date, there is a lack of comparative studies analysing these growth factors at a systemic and local level using colonic mucosa culture supernatant (MCS), and levels of these proteins have not been correlated with either the clinical, endoscopic or histological activity of IBD.
The aims of this study were: (i) to evaluate and compare the levels of the main angiogenic and lymphangiogenic factors (ALFs) and their receptors in serum and MCS from patients with active and quiescent IBD and healthy controls, and (ii) to correlate ALF levels with the endoscopic, clinical and histological activity, and with acute-phase reactants (APR) in patients with CD and UC. A complete characterization of angiogenic and lymphangiogenic processes should help to elucidate the pathogenesis of IBD and help to propose lines for future research in this field.
Materials and methods

Patients and controls
A prospective study was carried-out on 28 non-IBD controls and 72 patients with IBD (37 UC and 35 CD) that underwent a colonoscopy by medical criteria at Hospital Universitario de Fuenlabrada. IBD was diagnosed by clinical, radiological, endoscopic and histological criteria. 20 IBD location was established in accordance with the Montreal classification. 21 Patients were classified into active or quiescent CD and UC by endoscopic and clinical criteria, as defined below. All participants were asked to sign an informed consent form prior recruitment. The study was approved by the Research Ethics Committee at Hospital Universitario de Fuenlabrada and was conducted in accordance with the Declaration of Helsinki.
Endoscopic activity of IBD
Experienced gastroenterologists performed the ileocolonoscopies and graded the findings according to the Simple Endoscopic Score index for CD (SES-CD) and the endoscopic Mayo subscore for UC.
An SES-CD score between 0 and 2 suggested inactive disease in the colon and terminal ileum, 3-6 mildly active, 7-15 moderately active, and N 16 severely active disease. 22, 23 Regarding UC activity, a Mayo endoscopic subscore of 0 was considered inactive disease, 1 as mild activity, 2 as moderate activity and 3 as severe activity. 24 
Histological activity of IBD
All specimens were subjected to histological examination by an experienced pathologist.
In CD patients, histological activity was graded according to a scale of mucosal alterations developed by D'Haens et al. 25 The total histological score was a sum of the following variables: epithelial damage [normal (score = 0), focal pathology (score = 1) or extensive pathology (score = 2)]; architectural changes [normal (score = 0), moderately disturbed (score = 1) or severely disturbed (score = 2)]; infiltration of the lamina propria by mononuclear polymorphonuclear cells [normal (score = 0), moderate increase (score = 1), severe increase (score = 2)]; polymorphonuclear cells in the epithelium [in surface epithelium (score = 1), cryptitis (score = 2) and crypt abscess (score = 3)]; presence of erosion and/or ulcer and presence of granuloma [both scored as yes (score = 1) or no (score = 0)] and the number of biopsies e570
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affected [none (score = 0), b 33% (score = 1) and 33-66% (score = 2)]. Histological findings in UC patients were evaluated by using the Riley Index. 26 Six histological features of UC were considered: acute inflammatory cell infiltrate (polymorphonuclear cells in the lamina propria), crypt abscesses, mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate (round cells in the lamina propria), and crypt architectural irregularities. Each feature was graded on a four-point scale from 0 to 3.
Clinical activity of IBD
CD and UC clinical activity were ascertained by Crohn's Disease Activity Index (CDAI) and Mayo Score respectively. 27 A CDAI score below 150 indicated a quiescent disease; 150-250, mild disease; 251-350, moderate disease; and N 350, severe disease. A Mayo score ≤2 was considered disease remission; 3-5, mild disease; 6-10 moderate disease, and a score between 10 and 12 was considered severe disease.
APR
Blood leukocytes (normal range 4.0-11.0 10 9 /L), haemoglobin (normal range 13.0-17.3 g/dL), C-reactive protein (CRP, upper limit of normal 5 mg/L), platelet count (normal range: 140-450 10 9 /L) and erythrocyte sedimentation rate (ESR, upper limit of normal b 15 mm/h) were routinely determined before endoscopy procedures.
Samples and determinations
Three different specimens were obtained per subject:
-Blood samples for ALF measurement in serum: Peripheral blood was collected before colonoscopy in serum separator tubes, allowed to clot for 30 min at room temperature and centrifuged for 15 min at 3500 rpm. Serum was stored at − 70°C until analysis. -Tissue samples for ALF determination in MCS: Four colon biopsies were taken from non-affected (controls and non-active IBD patients) and/or affected mucosa (active IDB patients). In patients with active disease, samples from both inflamed and non-inflamed colonic mucosa were also taken when the disease extension was allowed. 
Results
Characteristics of patients and non-IBD controls
Seventy-two patients were studied, their mean age was 42 ± 12 years, 58% were female, and 28% were smokers. The control group consisted of 28 subjects with a mean age of 47 ± 6 years; 64% were female, and 35% were smokers. IBD diagnosis was CD in 49% and UC in 51% of the patients. Their mean disease duration was 9.6 ± 7.9 years. All the clinical and demographic characteristics of IBD patients and controls are shown in Table 1 . A clear association between smoking and concentrations of these proteins in both patients and control groups was not found (data not shown).
Determination of ALFs in Serum and colonic mucosa culture supernatant in patients with IBD and controls
Patients were classified into four groups according to endoscopic and clinical criteria: active (n = 21) and quiescent (n = 16) UC, active (n = 16) and inactive (n = 19) colonic CD (all of them with a CDAI b 150). Table 2 shows differences between serum levels of all ALFs and controls. VEGF concentration was higher in active UC patients than in patients in remission. Compared with controls, serum VEGFR3 and Ang1 concentrations were significantly higher in patients with active UC and serum Ang1 was higher in patients with active CD. Subjects with active or quiescent UC and CD had significantly higher serum levels of Tie2 than controls. Table 3 summarizes the results in MCS. When comparing IBD patients to controls, all studied ALFs except VEGFR3, were elevated in patients with active disease (p b 0.05). The same trend close to statistical significance was observed for VEGFR2 levels in patients with active CD (p = 0.054). ALF MCS levels observed in patients with quiescent IBD did not diverge from those of controls. An exception was observed for Ang2, which was lower in patients with inactive colonic CD than in controls (17.6 ± 6.6 vs. 21.5 ± 6.1 pg/mL per mg of tissue, p b 0.01).
Correlation between serum and MCS ALF levels
VEGFD, VEGFR3 and Tie2 serum levels showed a positive correlation with their corresponding concentrations in MCS (r = 0.25, r = 0.48, and r = 0.36, respectively; p b 0.05). This correlation was negative for PlGF (r = −0.45; p b 0.05). Further associations between serum and MCS levels were not found for the remaining ALFs (data not shown).
ALF levels and IBD clinical activity
According to CDAI and Mayo global indexes, disease activity was mild in 19% of patients (n = 14), moderate in 24% (n = 17), and 57% (n = 41) had no activity. Again, with the exception of VEGFR3, the levels of all the studied proteins in MCS were higher in patients with clinical activity than in those without it ( Fig. 1 ) (p b 0.05). In serum measurements, VEGFA, VEGFC and Ang1 were significantly higher in patients with clinical activity compared to those with inactive disease (VEGFA: 592 ± 447 vs. 395 ± 274 pg/mL, p = 0.02; VEGFC: 13.9 ± 4.8 vs. 11.8 ± 3.5 pg/mL, p = 0.03 and Ang1: 58.7 ± 17.6 vs. 50.8 ± 14.5 ng/mL, p = 0.04).
MCS levels of all ALFs, except VEGFR2 and VEGFR3, significantly correlated with CD activity, as measured by the CDAI index (p b 0.05). Regarding serum levels, VEGFR1, VEGFR2 and VEGFR3 correlated negatively with CD activity (Table 4) . In UC patients, a positive correlation was found between VEGFA, VEGFR1, PlGF, Ang1, Ang2 and Tie2 MCS levels, and the Mayo score ( Table 4 ). The correlation coefficients for these analyses were weaker than those for CDAI index in all cases. Serum VEGFA and VEGFC also correlated significantly with the Mayo score (Table 4) .
There was a significant correlation between endoscopic and clinical activity in both UC (r = 0.873; p b 0.001) and CD (r = 0.62; p b 0.001).
ALF levels and endoscopic activity of IBD
According to the Mayo subscore and the SES-CD endoscopic indexes, IBD activity was mild in 11% (n = 7) of patients, moderate in 31% (n = 19) and severe in 5% (n = 3). The remaining 53% (n = 33) did not show endoscopic activity.
MCS concentrations of all studied ALFs except VEGFR3 were significantly varied with the endoscopic activity (p b 0.05). VEGFR3 showed a similar trend, close to the threshold of statistical significance (p = 0.07) (Fig. 2) . These concentrations were higher in patients with endoscopic activity than in those without it (p b 0.05). These findings were not observed for serum ALFs (data not shown).
When we studied UC and CD separately, the Mayo endoscopic sub-score significantly correlated with all ALFs in MCS and the SES-CD score correlated with all except 
mean ± SD 7.6 ± 4.6 11.5 ± 9.7 - (Table 5 ).
In 60% (n = 22) of patients with endoscopic activity, biopsies of affected and non-affected mucosa were taken for comparison. As shown in Table 6 , PlGF, VEGFR2, Ang1 and Tie2 levels were higher in the affected tissue than in the non-affected tissue.
ALF levels and histological activity
Histological activity was mild in 20% of patients (n = 13), moderate in 34% (n = 22), severe in 8% (n = 5), and 38% (n = 25) had quiescent IBD. The concordance between endoscopic and histological activity indexes was higher in UC (κ = 0.73) than in CD patients (κ = 0.55). Levels of all the studied proteins in MCS also correlated significantly (p b 0.01) with histological activity. These concentrations diverged with the severity of histological lesions, with the highest ALF levels corresponding to patients with severe lesions (Fig. 3) .
Only VEGFA and Ang1 serum levels were higher in patients with histological activity than in those without it (577 ± 426 vs. 346 ± 239 pg/mL, p b 0.01 and 57.8 ± 16.4 vs. 47.2 ± 14.6 ng/mL, p b 0.05, respectively). Further differences in serum ALF levels related to histological activity were not observed (data not shown).
Association of ALFs with APR
The correlations between serum ALFs and APR are shown in Table 7 . Ang1 and VEGFA correlated significantly with CRP and platelet and leukocyte counts. There was a significant correlation between platelet count and VEGFA (r = 0.293; p = 0.005); VEGFC (r = 0.231; p = 0.028); VEGFR1(r = 0.238; Vascular endothelial growth factor A and D (VEGFA, VEGFD), placenta growth factor (PlGF) and vascular endothelial growth factor receptor 1 (VEGFR1) concentrations are expressed in pg/mL, all other proteins in ng/mL. Abbreviations: AUC (active ulcerative colitis patients), QUC (quiescent ulcerative colitis patients), ACD (colonic active Crohn's disease patients), QCD (colonic inactive Crohn's disease patients). ⁎ Significant differences compared to control (p = 0.05). # Significant differences compared to patients in remission (p = 0.05). 
ALFs levels in serum and MCS as predictors of disease activity
MCS levels of all studied ALFs except VEGFR3 were significantly associated with endoscopic and clinical activity, and all of them with histological activity (p b 0.05; Figs. 1, 2 and 3). The utility of these ALFs to predict endoscopic, histological and clinical activity of IBD was analysed based on the area under the ROC curve (AUC). Ang2 was the best predictor of endoscopic (AUC: 0.83, cut-off at 18.5 ng/mL, 86% sensitivity and 66% specificity), histological (AUC: 0.85, cut-off at 18.5 ng/mL, 89% sensitivity and 72% specificity) and clinical activity (AUC: 0.90, cut-off at 22.1 ng/mL, 83% sensitivity and 84% specificity). For ALFs in serum, the AUCs were lower than those for the corresponding ALFs in MCS (data not shown). VEGFA and Ang-1 levels were more increased in patients with histological activity than in those without it. The AUC for the diagnosis of histological activity was 0.68 for Ang1 (cut-off at 52.0 ng/mL: 64% sensitivity and 68% specificity) and 0.67 for VEGFA (cut-off at 340.6 ng/mL: 64% sensitivity and 60% specificity).
VEGFA, VEGFC and Ang1 had higher serum levels (p b 0.05) in patients with clinically-active IBD compared to those with inactive disease. The AUC for the diagnosis of this clinical activity was lower than 0.65 for all ALFs in serum except for VEGFA (0.67). The cut-off point with the best sensitivity (60%) and specificity (68%) for the identification of clinical activity was 379 pg/mL/per mg of tissue for serum VEGFA.
Regarding endoscopic activity, a significant positive correlation was only found between Ang1 serum levels and the SES-CD index, and between VEGFA serum levels and the Mayo endoscopic sub-score (Table 5 ). To predict endoscopic activity in CD patients, the AUC for Ang1 in serum was 0.65 (cut-off at 47.8 ng/mL, 67% sensitivity and 52% specificity). In UC patients, the AUC for the diagnosis of endoscopic activity was 0.72 for VEGFA (cut-off at 341 ng/mL, 85% sensitivity and 64% specificity).
Discussion
The role played by angiogenesis and lymphangiogenesis in IBD is still being elucidated. In our study, ALF levels were locally high in MCS. All studied proteins except VEGFR3 were significantly higher in patients with endoscopic and clinical IBD activity compared to those in remission. In colorectal cancer, immunohistochemical studies carried out in both normal and tumour tissues show that only a small proportion of blood vessels express VEGFR3. The expression of this factor was not associated with tumour stage, but it was closely related with the presence of inflammatory infiltrate. 30 It has been reported that infiltrating macrophages are an important source of ALFs such as VEGFA and inflammatory cytokines. 31 These cytokines may modulate the expression of VEGF family members, and have been shown to up-regulate expression of VEGFR2, but not VEGFR3, in endothelial cells. 30, 32 There is no clear candidate molecule that might up-regulate the expression of VEGFR3. Paavonen et al. 33 have observed low levels of this protein in inflammatory skin ulcers in humans, together with transient expression in experimental wounds in a pig model. They suggest that this transient expression may be an integral part of normal wound healing and the relative absence of lymphatic vessels might account for impaired healing in chronic wounds. The unchanged VEGFR3 levels in MCS might be consistent with an IBD associated failure to adequately mobilize lymphatics leading to an overall hypofunction of this vasculature. These data are in accordance with Alexander et al. 34 , who reported an inability to mobilize lymphatic expansion as an adaptive response in IBD. Lymphatic failure in chronic disease would result in accumulation of cytokines and immune cells exacerbating IBD.
The independent and uncertain behaviour of VEGFR3 in other pathologies and animal models coincide with the lack of differences in the levels of this protein between patients with active IBD compared to inactive IBD and also vs. healthy controls shown in this study. The up-regulation of VEGFR2 and the stability of VEGFR3 levels suggest that the prolymphangiogenic function of VEGFC and D could be driven by VEGFR2 instead of the VEGFR3 pathway during the active period of IBD. This is the first study to analyse the levels of VEGFR3 in supernatant from primary cultures of bowel mucosa and their association with this disease.
With respect to the remaining proteins studied, most of the previous investigations on ALFs have been carried out in serum and tissue by immunohistochemistry. Recent publications suggest that altered angiogenesis may be a critical component of IBD pathogenesis. 15, 35, 36 The exception is the study by Kapsoritakis et al. 37 , who observed weaker VEGFA immunostaining intensity in patients with active CD vs. healthy controls, while that of patients with UC was similar, suggesting that the course of UC is not VEGFA-dependent. Figure 2 Comparison of angiogenic and lymphangiogenic factor levels in colonic mucosa culture supernatant according to endoscopic activity. All concentrations are expressed in pg/mL per mg of tissue, except vascular endothelial growth factor receptor 3 (VEGFR3) concentration, which is expressed in pg/mL/10 per mg of tissue. Significant differences **p = 0.01.*p = 0.05.
The differences with our results are probably due to the method used to assess the levels of the proteins studied. The authors Kapsoritakis et al. measured tissue expression while we evaluated levels of soluble ALFs. Both immunohistochemistry and MCS levels reflect ALF expression in colonic mucosa, but the latter detects proteins that have been released to the surrounding medium and are not anchored to a sub-cellular location.
The biological meaning of elevated ALF concentrations in MCS with respect to the development of IBD is unknown. Our results concur with those of previous studies, showing increased expression of VEGFA in colonic mucosa from IBD patients. 16, 38, 42 The intestinal mucosa has been considered a possible origin of elevated VEGFA serum levels in patients with active IBD. 43 Clinical studies and animal models of experimental colitis also showed increased microvascular density in the mucosal and submucosal tissue 15, 17, 35 and up-regulation of pro-angiogenic factors such as VEGFA, 16, [38] [39] [40] [41] [42] basic fibroblast growth factor (bFGF), 42 platelet-derived growth factor (PDGF), 42 and placental growth factor (PlGF). 44 Concerning other chronic inflammatory diseases, Schroeder et al. found elevated expression of VEGFA, VEGFR1, -R2, Tie2, and the Ang1/Ang2 ratio in synovial tissue from patients with rheumatoid arthritis compared to patients with osteoarthritis. 6 Regarding the site of the tissue collection, Griga et al. 41 reported significantly higher VEGFA immunohistochemical staining in the epithelium and the lamina propia of inflamed colonic mucosa of patients with IBD, compared with noninflamed patients. The same authors 41 observed increased expression of VEGFA in MCS from patients with active IBD compared with a group of patients with irritable bowel syndrome. To our knowledge, further studies comparing both affected and non-affected mucosa from the same subject have not been reported. In our patients, VEGFA levels tended to be higher in MCS from affected mucosa (p = 0.07) PlGF, VEGFC, VEGFR2, Ang1 and Tie2 concentrations were significantly higher in areas with macroscopic damage than in non-affected areas. High levels of the remaining proteins were found in both affected and nonaffected mucosa, but the values observed in non-affected tissue were still higher than those found in patients in remission. These results reflect that in patients with active disease, macroscopically "normal" mucosa is sometimes altered at the microscopic and/or molecular level.
With respect to clinical disease indexes, most of the studies show a correlation between serum VEGFA levels and disease activity. 39, 42, 45, 46 Kanazawa et al. 42 reported increased VEGFA levels in the serum and colonic tissue of patients with active UC. Likewise, Bousvaros et al. 46 showed that serum VEGFA levels in children and young adults were elevated during active CD. In our study, serum VEGFA levels correlated with clinical activity in UC but not in CD patients. The same was found with respect to endoscopic activity. In contrast, Ang1 correlated with endoscopic activity in patients with CD, but not with UC, while no association was found with clinical activity. These observations should be considered with caution because, although p values were significant, the correlation coefficients were not very high. Finally, serum concentrations of both factors were higher in patients with a histological diagnosis of active vs. non-active disease, suggesting that they are a reflection of the events that are taking place at the microscopic level. VEGFA and Ang1 also correlated with the inflammatory marker CRP and with an increase in the number of leukocytes and platelets, which release both angiogenic factors during inflammation processes. There was a good correlation between ALFs in MCS and the endoscopic, histological and clinical activity of the IBD. This gives us an idea of the severity of the injuries and, although most of the ALFs could be useful as IBD markers, Ang2 seems to be the most accurate. Ang1 and Ang2 are antagonistic ligands that bind to the extracellular domain of Tie2 receptor, which is almost exclusively expressed by endothelial cells. In critically ill patients, a marked imbalance Figure 3 Comparison of angiogenic and lymphangiogenic factor levels in colonic mucosa culture supernatant according histological activity. All concentrations are expressed in pg/mL per mg of tissue, except vascular endothelial growth factor receptor 3 (VEGFR3) concentration, which is expressed in pg/mL/10 per mg of tissue. **Significant differences p b 0.01. of the angiopoietin-Tie system in favour of Ang2 has been confirmed. Several studies evidence that Ang2 concentrations correlate with the severity of the illness.
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Our results do not show a good correlation between ALF levels in serum and MCS, indicating that local variations in the concentrations of the factors studied do not correspond with circulating proteins. Nevertheless, in our study, ALF alterations at a local level appear to be a fact, although in view of the results obtained, we cannot determine whether such variations are a cause or a consequence of IBD lesions that perpetuate the existing inflammation. In spite of this, the study of some of these ALFs as possible targets in new therapies for IBD constitutes a key new line of research. Our ideal would be to find a serum activity marker that could avoid the performance of aggressive procedures like colonoscopy. Only serum VEGFA and Ang1 seem to be useful markers of endoscopic, histological and clinical activity. In view of our results, serum ALF levels cannot be recommended as predictors of IBD activity at the moment.
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